Looking For Genetic and Environmental Risk Factors and Therapeutic Aspects in Cervical Artery Dissections
CADISP
1 other identifier
observational
4,169
9 countries
24
Brief Summary
The main purpose of this study is to look for genetic and environmental risk factors of cervical artery dissections, a major cause of ischemic stroke in young adults, in a large multicenter case-control trial
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2005
Longer than P75 for all trials
24 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2005
CompletedFirst Submitted
Initial submission to the registry
April 8, 2008
CompletedFirst Posted
Study publicly available on registry
April 14, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2009
CompletedOctober 21, 2009
October 1, 2009
3.5 years
April 8, 2008
October 20, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
association of genetic polymorphisms with cervical artery dissections
2009
Secondary Outcomes (2)
association of environmental risk factors with cervical artery dissections
2009
gene-environment interactions
2009
Study Arms (3)
1
CAD-group (Cervical Artery Dissection - group): consecutive patients with cervical artery dissection, with or without associated cerebral ischemia, hospitalized in one of the participating neurological centers; standardized inclusion and exclusion criteria apply
2
IS-group (Ischemic Stroke - Group): patients selected among consecutive patients hospitalized for an ischemic stroke without CAD, in the same centers as patients from group1, frequency-matched on age and gender with group1; standardized inclusion and exclusion criteria apply
3
HC-group (Healthy Control - Group): DNA of healthy individuals from existing DNA-databases will be used as controls for the Belgian, French, German and Swiss centers; the other centers are recruiting their own age- and sex-matched healthy controls; individuals from the 3 groups (CAD, IS and HC) are strictly matched on geographical origin in order to avoid stratification bias
Eligibility Criteria
groups 1 and 2: hospital-based, neurology departments group 3: community samples
You may qualify if:
- Typical radiological aspect of dissection\* in a cervical artery (carotid and/or vertebral);\* Mural hematoma, pseudoaneurysm, long tapering stenosis, intimal flap, double lumen, or occlusion \> 2 cm above the carotid bifurcation revealing a pseudo aneurysm or a long tapering stenosis after recanalisation
- Written informed consent
You may not qualify if:
- Purely intracranial dissection
- Dissection occurring after an endovascular procedure
- Known mendelian genetic disorder that can explain the dissection (e.g. vascular Ehlers-Danlos syndrome)
- GROUP2:
- Recent ischemic stroke
- No signs of CAD on extracranial duplex sonography and angiography (digital subtraction or magnetic resonance or CT), performed \< 7 days after the stroke
- Written informed consent
- Possible cerebral ischemia but normal cerebral imaging
- CAD cannot be ruled out (e.g.persistent arterial occlusion without mural hematoma)
- Endovascular or surgical procedure on the coronary, cervical or cerebral arteries during the 48 hours preceding the cerebral infarction
- Cardiopathies with a very high embolic risk (Mechanical prosthetic valves, mitral stenosis with atrial fibrillation, intracardiac tumor, infectious endocarditis, myocardial infarction\<4 months)
- Arterial vasospasm following a subarachnoid haemorrhage
- Auto-immune disease possibly responsible for the cerebral infarction
- Known monogenic disease responsible for the cerebral infarction
- GROUP3:
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (24)
Sanatorio Allende
Córdoba, 5000, Argentina
Department of Neurology, University Hospital of Brussels (ULB)
Brussels, 1070, Belgium
Department of Neurology, University Hospital of Leuven
Leuven, 3000, Belgium
Department of Neurology, Helsinki University Central Hospital
Helsinki, 00290, Finland
Department of Neurology, University Hospital of Amiens
Amiens, 80000, France
Department of Neurology, University Hospital of Besançon
Besançon, 25000, France
Department of Neurology, University Hospital of Dijon
Dijon, 21000, France
Department of Neurology, University Hospital of Lille
Lille, 59000, France
Inserm U744 Institut Pasteur de Lille
Lille, 59000, France
Department of Neurology, University Hospital Pitié-Salpêtrière
Paris, 75013, France
Department of Neurology, University Hospital Sainte-Anne
Paris, 75015, France
Rehabilitation Center, Schmieder-Klinik
Heidelberg, 62120, Germany
Department of Neurology, University Hospital of Heidelberg
Heidelberg, 69120, Germany
Department of Neurology, Hospital of Ludwigshafen
Ludwigshafen, 67063, Germany
Department of Neurology, University Hospital of Munich
Munich, 81377, Germany
Department of Neurology, University Hospital of Brescia
Brescia, 25100, Italy
Department of Neurology, Ospedale Maggiore Policlinico di Milano
Milan, 20100, Italy
Ospedale Milano San Raffaele
Milan, 20132, Italy
Department of Neurology, University Hospital Milano-Bicocca
Monza, 20052, Italy
Department of Neurology, University Hospital of Perugia
Perugia, 06081, Italy
Rehabilitation Center, IRCCS Santa Lucia, Roma
Rome, 00100, Italy
Department of Neurology, University Hospital of Basel
Basel, 4031, Switzerland
Department of Neurology, Cerrahpasa Medical Faculty, Istanbul University
Istanbul, Turkey (Türkiye)
Department of Neuroscience, St George's University Hospital of London
London, SW170RE, United Kingdom
Related Publications (2)
Engelter ST, Brandt T, Debette S, Caso V, Lichy C, Pezzini A, Abboud S, Bersano A, Dittrich R, Grond-Ginsbach C, Hausser I, Kloss M, Grau AJ, Tatlisumak T, Leys D, Lyrer PA; Cervical Artery Dissection in Ischemic Stroke Patients (CADISP) Study Group. Antiplatelets versus anticoagulation in cervical artery dissection. Stroke. 2007 Sep;38(9):2605-11. doi: 10.1161/STROKEAHA.107.489666. Epub 2007 Jul 26.
PMID: 17656656BACKGROUNDDebette S, Metso TM, Pezzini A, Engelter ST, Leys D, Lyrer P, Metso AJ, Brandt T, Kloss M, Lichy C, Hausser I, Touze E, Markus HS, Abboud S, Caso V, Bersano A, Grau A, Altintas A, Amouyel P, Tatlisumak T, Dallongeville J, Grond-Ginsbach C; CADISP-group. CADISP-genetics: an International project searching for genetic risk factors of cervical artery dissections. Int J Stroke. 2009 Jun;4(3):224-30. doi: 10.1111/j.1747-4949.2009.00281.x.
PMID: 19659826BACKGROUND
Biospecimen
DNA, plasma, serum
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Stéphanie Debette, MD, PhD
Department of Neurology (EA2691), University Hospital of Lille; Inserm, U744, Pasteur Institute, Lille, France
- STUDY CHAIR
Caspar Grond-Ginsbach, PhD
Department of Neurology, University Hospital of Heidelberg, Germany
- PRINCIPAL INVESTIGATOR
Didier Leys, MD PhD
Department of Neurology (EA2691), University Hospital of Lille, France
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Sponsor Type
- NETWORK
Study Record Dates
First Submitted
April 8, 2008
First Posted
April 14, 2008
Study Start
July 1, 2005
Primary Completion
January 1, 2009
Study Completion
September 1, 2009
Last Updated
October 21, 2009
Record last verified: 2009-10